Trial Condition(s):

Overactive Bladder

FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder patients during a 3 Months period (FREEDOM)

Bayer Identifier:

13027

ClinicalTrials.gov Identifier:

NCT00921245

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Patient perspective on Overactive Bladder and symptoms experienced after administration of Darifenacin

Inclusion Criteria
- Male and female patients > 18 years with symptoms of overactive bladder.
Exclusion Criteria
- Contraindications for the treatment with Darifenacin prolonged-release tablets according to the registered package insert.
 - Pregnancy and lactation. Women of childbearing potential have to use an acceptable method of contraception.
 - Concomitant treatment with drugs known to affect mainly the urinary bladder function (e.g. anticholinergics, antispasmodics) at any time during the study. Concomitant treatment with botulinum toxin, capsaicin or resiniferatoxin at any time during the study and treatment with botulinum toxin, capsaicin or resiniferatoxin in the last 6 months prior to Visit 1.

Trial Summary

Enrollment Goal
9
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Emselex (Darifenacin, BAY79-4998)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, South Africa

Status
Completed
 

Trial Design